Promising combo trial for brain metastases halted after just 3 patients

NCT ID NCT05746481

Terminated Disease control Sponsor: Liza Villaruz, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested two immune-boosting drugs, tiragolumab and atezolizumab, with or without chemotherapy, in people with non-small cell lung cancer that had spread to the brain. The goal was to see if the combination could control the brain tumors and delay the need for radiation. However, the study was terminated early after enrolling only 3 participants, so no meaningful conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tiragolumab and atezolizumab (immune-boosting drugs)
What this could lead to: If it worked, this combination might help control lung cancer that has spread to the brain without needing radiation.
What could go wrong: The trial was terminated early with only 3 participants, so we have very little data. It is unclear if the drugs are safe or effective for this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.